Five Year Age-Standardized Relative Survival Ratios (RSR) for Cancers Diagnosed 2012–2018 Complete Method, Follow-Up Through 2018 for Melanoma of the Skin

| NAACCR U.S. COMBINED Subgroup | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|-------------------------------|-------------------|------|-------------|---------|------|-------------|---------|------|-------------|
| | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | 494,463 | 92.6 | 92.4 - 92.7 | 290,028 | 90.9 | 90.7 - 91.1 | 204,435 | 94.2 | 94.0 - 94.4 |
| Race | | | | | | | | | |
| White | 469,588 | 92.3 | 92.1 - 92.4 | 276,961 | 90.5 | 90.3 - 90.7 | 192,627 | 94.0 | 93.8 - 94.2 |
| Black | 2,332 | 71.1 | 68.3 - 73.8 | 1,103 | 66.8 | 62.4 - 70.8 | 1,229 | 74.8 | 71.3 - 78.1 |
| Stage | | | | | | | | | |
| Localized | 387,023 | 98.2 | 98.0 - 98.3 | 223,197 | 97.6 | 97.4 - 97.8 | 163,826 | 98.8 | 98.6 - 99.0 |
| Regional | 45,877 | 73.2 | 72.5 - 73.8 | 29,117 | 71.1 | 70.2 - 72.0 | 16,760 | 76.1 | 75.1 - 77.1 |
| Distant | 25,069 | 35.7 | 34.8 - 36.6 | 17,058 | 33.7 | 32.5 - 34.8 | 8,011 | 38.7 | 37.3 - 40.2 |
| Unstaged | 43,324 | 91.5 | 91.0 - 92.0 | 25,590 | 90.4 | 89.6 - 91.1 | 17,734 | 92.4 | 91.7 - 93.1 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | 63,639 | 95.1 | 94.8 - 95.3 | 23,929 | 92.1 | 91.7 - 92.6 | 39,710 | 96.8 | 96.6 - 97.1 |
| 45-54 | 69,852 | 93.6 | 93.3 - 93.9 | 34,510 | 91.4 | 91.0 - 91.8 | 35,342 | 95.7 | 95.4 - 96.0 |
| 55-64 | 111,142 | 92.7 | 92.4 - 93.0 | 65,679 | 91.2 | 90.8 - 91.6 | 45,463 | 94.9 | 94.6 - 95.3 |
| 65-74 | 125,341 | 92.1 | 91.7 - 92.4 | 82,963 | 91.4 | 91.0 - 91.8 | 42,378 | 93.3 | 92.8 - 93.7 |
| 75+ | 126,722 | 86.9 | 86.3 - 87.5 | 84,516 | 86.6 | 85.8 - 87.4 | 42,206 | 87.5 | 86.5 - 88.5 |

| NAACCR | CANADIAN |
|--------|----------|
|--------|----------|

| COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|------|-------------|--------|------|-------------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | 41,473 | 89.8 | 89.3 - 90.3 | 22,746 | 87.7 | 87.0 - 88.5 | 18,727 | 92.1 | 91.4 - 92.7 |
| Stage ² | | | | | | | | | |
| Localized | 9,332 | 96.1 | 95.3 - 96.8 | 4,854 | 95.1 | 93.9 - 96.0 | 4,478 | 97.2 | 96.0 - 98.1 |
| Regional | 1,569 | 67.0 | 63.8 - 69.9 | 957 | 63.3 | 59.0 - 67.2 | 612 | 71.8 | 66.8 - 76.2 |
| Distant | 606 | 28.1 | 23.0 - 33.5 | 401 | 30.8 | 23.9 - 37.9 | 205 | 23.1 | 15.6 - 31.6 |
| Unstaged | 23,869 | 89.9 | 89.2 - 90.5 | 13,238 | 88.0 | 86.9 - 88.9 | 10,631 | 91.8 | 91.0 - 92.6 |
| Age Group ² | | | | | | | | | |
| 15-44 | 4,960 | 94.4 | 93.5 - 95.2 | 1,852 | 92.3 | 90.5 - 93.7 | 3,108 | 95.7 | 94.6 - 96.5 |
| 45-54 | 5,791 | 92.0 | 91.0 - 92.9 | 2,730 | 90.2 | 88.6 - 91.6 | 3,061 | 93.6 | 92.2 - 94.7 |
| 55-64 | 9,438 | 89.2 | 88.2 - 90.2 | 5,152 | 86.1 | 84.6 - 87.5 | 4,286 | 92.9 | 91.6 - 94.0 |
| 65-74 | 10,109 | 89.2 | 88.0 - 90.3 | 6,200 | 87.7 | 86.0 - 89.2 | 3,909 | 91.5 | 89.8 - 92.9 |
| 75+ | 11,363 | 80.0 | 78.1 - 81.8 | 6,922 | 78.2 | 75.6 - 80.6 | 4,441 | 82.7 | 79.7 - 85.4 |

| NAACCR NORTH AMERICA |
|----------------------|
| COMBINED |

| COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|------|-------------|---------|------|-------------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | 535,936 | 92.4 | 92.2 - 92.5 | 312,774 | 90.7 | 90.5 - 90.9 | 223,162 | 94.0 | 93.8 - 94.2 |
| Stage ² | | | | | | | | | |
| Localized | 396,355 | 98.1 | 98.0 - 98.2 | 228,051 | 97.5 | 97.3 - 97.7 | 168,304 | 98.7 | 98.5 - 98.9 |
| Regional | 47,446 | 72.9 | 72.2 - 73.5 | 30,074 | 70.7 | 69.8 - 71.6 | 17,372 | 75.9 | 74.9 - 76.9 |
| Distant | 25,675 | 35.5 | 34.6 - 36.4 | 17,459 | 33.6 | 32.5 - 34.7 | 8,216 | 38.4 | 36.9 - 39.8 |
| Unstaged | 67,193 | 90.9 | 90.5 - 91.3 | 38,828 | 89.5 | 88.9 - 90.1 | 28,365 | 92.3 | 91.7 - 92.8 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | 68,599 | 95.0 | 94.8 - 95.2 | 25,781 | 92.1 | 91.7 - 92.6 | 42,818 | 96.8 | 96.5 - 97.0 |
| 45-54 | 75,643 | 93.5 | 93.2 - 93.7 | 37,240 | 91.3 | 90.9 - 91.7 | 38,403 | 95.5 | 95.2 - 95.8 |
| 55-64 | 120,580 | 92.4 | 92.2 - 92.7 | 70,831 | 90.8 | 90.4 - 91.2 | 49,749 | 94.8 | 94.4 - 95.1 |
| 65-74 | 135,450 | 91.8 | 91.5 - 92.1 | 89,163 | 91.2 | 90.7 - 91.6 | 46,287 | 93.1 | 92.6 - 93.6 |
| 75+ | 138,085 | 86.4 | 85.8 - 86.9 | 91,438 | 86.0 | 85.2 - 86.7 | 46,647 | 87.1 | 86.1 - 88.0 |

Abbreviations: RSR, Relative Survival Ratio; CI, Confidence Interval

N/A Not applicable, statistics not calculated.

* All statistics are suppressed when fewer than 10 cases were reported for the specific cancer. Survival statistics are suppressed when the standard error was greater than or equal to 10% or the difference between the upper and lower confidence intervals was greater than 40%.

Relative survival ratio (RSR) and confidence interval (CI) values are not age-standardized.

² Canadian data is comprised of 2015-2017 only due to changes in coding of stage starting in 2018.

Five Year Age-Standardized Relative Survival Ratios (RSR) for Cancers Diagnosed 2012-2018 Complete Method, Follow-Up Through 2018 for Female Breast

| NAACCR U.S. COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|-----|--------|-------|-----|--------|-----------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 1,526,050 | 89.6 | 89.5 - 89.7 |
| Race | | | | | | | | | |
| White | N/A | N/A | | N/A | N/A | | 1,255,679 | 90.6 | 90.4 - 90.7 |
| Black | N/A | N/A | | N/A | N/A | | 181,312 | 81.7 | 81.3 - 82.1 |
| Stage | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 997,558 | 98.4 | 98.2 - 98.5 |
| Regional | N/A | N/A | | N/A | N/A | | 418,674 | 83.2 | 83.0 - 83.5 |
| Distant | N/A | N/A | | N/A | N/A | | 90,347 | 28.7 | 28.3 - 29.2 |
| Unstaged | N/A | N/A | | N/A | N/A | | 36,545 | 66.6 | 65.8 - 67.4 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 150,677 | 88.8 | 88.6 - 89.0 |
| 45-54 | N/A | N/A | | N/A | N/A | | 287,890 | 91.0 | 90.8 - 91.1 |
| 55-64 | N/A | N/A | | N/A | N/A | | 393,704 | 90.4 | 90.3 - 90.6 |
| 65-74 | N/A | N/A | | N/A | N/A | | 402,496 | 91.3 | 91.1 - 91.5 |
| 75+ | N/A | N/A | | N/A | N/A | | 293,770 | 86.9 | 86.5 - 87.2 |

| NAACCR CANADIAN COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|-----------------------------|-------------------|-----|--------|-------|------------|--------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 133,722 | 88.1 | 87.7 - 88.5 |
| Stage ² | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 67,774 | 97.5 | 97.0 - 97.9 |
| Regional | N/A | N/A | | N/A | N/A | | 36,494 | 83.7 | 83.0 - 84.5 |
| Distant | N/A | N/A | | N/A | N/A | | 7,138 | 32.8 | 31.2 - 34.4 |
| Unstaged | N/A | N/A | | N/A | N/A | | 3,829 | 63.5 | 61.3 - 65.6 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 12,553 | 88.6 | 87.8 - 89.3 |
| 45-54 | N/A | N/A | | N/A | N/A | | 25,954 | 91.5 | 91.0 - 92.0 |
| 55-64 | N/A | N/A | | N/A | N/A | | 33,598 | 90.8 | 90.3 - 91.3 |
| 65-74 | N/A | N/A | | N/A | N/A | | 34,689 | 91.1 | 90.5 - 91.6 |
| 75+ | N/A | N/A | | N/A | N/Δ | | 27 200 | 81.5 | 804 - 826 |

| NAACCR NORTH AMERICA COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|----------------------------------|-------------------|-----|-----------------|-------|-----|--------|-----------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 1,659,772 | 89.5 | 89.4 - 89.6 |
| Stage ² | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 1,065,332 | 98.3 | 98.2 - 98.4 |
| Regional | N/A | N/A | | N/A | N/A | | 455,168 | 83.3 | 83.0 - 83.5 |
| Distant | N/A | N/A | | N/A | N/A | | 97,485 | 29.1 | 28.6 - 29.5 |
| Unstaged | N/A | N/A | | N/A | N/A | | 40,374 | 66.3 | 65.6 - 67.1 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 163,230 | 88.8 | 88.6 - 89.0 |
| 45-54 | N/A | N/A | | N/A | N/A | | 313,844 | 91.0 | 90.9 - 91.2 |
| 55-64 | N/A | N/A | | N/A | N/A | | 427,302 | 90.5 | 90.3 - 90.6 |
| 65-74 | N/A | N/A | | N/A | N/A | | 437,185 | 91.3 | 91.1 - 91.5 |
| 75+ | N/A | N/A | <u>. </u> . | N/A | N/A | | 320,970 | 86.4 | 86.1 - 86.7 |

Abbreviations: RSR, Relative Survival Ratio; CI, Confidence Interval

^{*} All statistics are suppressed when fewer than 10 cases were reported for the specific cancer. Survival statistics are suppressed when the standard error was greater than or equal to 10% or the difference between the upper and lower confidence intervals was greater than 40%.

Relative survival ratio (RSR) and confidence interval (CI) values are not age-standardized.

Canadian data is comprised of 2015-2017 only due to changes in coding of stage starting in 2018.

Five Year Age-Standardized Relative Survival Ratios (RSR) for Cancers Diagnosed 2012–2018 Complete Method, Follow-Up Through 2018 for Cervix Uteri

| NAACCR U.S. COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|-----|--------|-------|-----|--------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | .,, | N/A | N/A | , | 83,219 | 61.5 | 61.0 - 62.0 |
| Race | | | | | | | | | |
| White | N/A | N/A | | N/A | N/A | | 63,709 | 62.0 | 61.5 - 62.6 |
| Black | N/A | N/A | | N/A | N/A | | 13,043 | 55.1 | 53.9 - 56.3 |
| Stage | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 36,438 | 85.1 | 84.3 - 86.0 |
| Regional | N/A | N/A | | N/A | N/A | | 29,087 | 56.8 | 56.0 - 57.6 |
| Distant | N/A | N/A | | N/A | N/A | | 12,699 | 17.7 | 16.8 - 18.6 |
| Unstaged | N/A | N/A | | N/A | N/A | | 5,128 | 55.2 | 53.3 - 56.9 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 31,200 | 78.8 | 78.2 - 79.4 |
| 45-54 | N/A | N/A | | N/A | N/A | | 18,956 | 67.6 | 66.7 - 68.4 |
| 55-64 | N/A | N/A | | N/A | N/A | | 16,447 | 59.5 | 58.5 - 60.5 |
| 65-74 | N/A | N/A | | N/A | N/A | | 10,009 | 51.8 | 50.4 - 53.2 |
| 75+ | N/A | N/A | | N/A | N/A | | 6,630 | 36.3 | 34.4 - 38.3 |

| COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|-----|--------|-------|-----|--------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 7,520 | 68.0 | 66.4 - 69.6 |
| Stage ² | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 3,140 | 89.0 | 86.5 - 91.1 |
| Regional | N/A | N/A | | N/A | N/A | | 2,018 | 61.6 | 58.7 - 64.3 |
| Distant | N/A | N/A | | N/A | N/A | | 672 | 21.4 | 17.7 - 25.2 |
| Unstaged | N/A | N/A | | N/A | N/A | | 555 | 58.5 | 53.5 - 63.2 |
| Age Group ² | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 3,235 | 86.1 | 84.5 - 87.6 |
| 45-54 | N/A | N/A | | N/A | N/A | | 1,621 | 74.2 | 71.4 - 76.8 |
| 55-64 | N/A | N/A | | N/A | N/A | | 1,290 | 67.5 | 64.1 - 70.7 |
| 65-74 | N/A | N/A | | N/A | N/A | | 782 | 57.3 | 52.2 - 62.0 |
| 75+ | N/A | N/A | | N/A | N/A | | 599 | 40.5 | 34.9 - 46.0 |

| NAACCR NORTH AMERIC | CA |
|---------------------|----|
| COMBINED | |

| COMBINED Subgroup | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|-----|--------|-------|-----|--------|---------|------|-------------|
| | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 90,739 | 62.1 | 61.6 - 62.5 |
| Stage ² | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 39,578 | 85.6 | 84.7 - 86.3 |
| Regional | N/A | N/A | | N/A | N/A | | 31,105 | 57.2 | 56.4 - 58.0 |
| Distant | N/A | N/A | | N/A | N/A | | 13,371 | 17.9 | 17.0 - 18.8 |
| Unstaged | N/A | N/A | | N/A | N/A | | 5,683 | 55.6 | 53.9 - 57.3 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 34,435 | 79.5 | 79.0 - 80.0 |
| 45-54 | N/A | N/A | | N/A | N/A | | 20,577 | 68.1 | 67.3 - 68.9 |
| 55-64 | N/A | N/A | | N/A | N/A | | 17,737 | 60.1 | 59.1 - 61.1 |
| 65-74 | N/A | N/A | | N/A | N/A | | 10,791 | 52.2 | 50.9 - 53.5 |
| 75+ | N/A | N/A | | N/A | N/A | | 7,229 | 36.9 | 35.1 - 38.7 |

Abbreviations: RSR, Relative Survival Ratio; CI, Confidence Interval
N/A Not applicable, statistics not calculated.

* All statistics are suppressed when fewer than 10 cases were reported for the specific cancer. Survival statistics are suppressed when the standard error was greater than or equal to 10% or the difference between the upper and lower confidence intervals was greater than 40%.

1 Relative survival ratio (RSR) and confidence interval (CI) values are not age-standardized.

2 Constitute that is experienced (2015 2017 and what is parties agreement agreement age.

² Canadian data is comprised of 2015-2017 only due to changes in coding of stage starting in 2018.

Five Year Age-Standardized Relative Survival Ratios (RSR) for Cancers Diagnosed 2012-2018 Complete Method, Follow-Up Through 2018 for Corpus & Uterus, NOS

| NAACCR U.S. COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|------------------------|-------------------|-----|--------|-------|-----|--------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 351,351 | 77.9 | 77.6 - 78.2 |
| Race | | | | | | | | | |
| White | N/A | N/A | | N/A | N/A | | 289,205 | 80.4 | 80.1 - 80.7 |
| Black | N/A | N/A | | N/A | N/A | | 41,827 | 59.6 | 58.8 - 60.4 |
| Stage | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 240,141 | 92.8 | 92.5 - 93.1 |
| Regional | N/A | N/A | | N/A | N/A | | 65,708 | 65.8 | 65.2 - 66.4 |
| Distant | N/A | N/A | | N/A | N/A | | 31,684 | 17.4 | 16.8 - 18.0 |
| Unstaged | N/A | N/A | | N/A | N/A | | 14,639 | 53.8 | 52.7 - 55.0 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 23,562 | 90.3 | 89.8 - 90.8 |
| 45-54 | N/A | N/A | | N/A | N/A | | 51,751 | 87.4 | 87.0 - 87.8 |
| 55-64 | N/A | N/A | | N/A | N/A | | 119,992 | 83.7 | 83.4 - 84.0 |
| 65-74 | N/A | N/A | | N/A | N/A | | 101,833 | 78.1 | 77.7 - 78.5 |
| 75+ | N/A | N/A | | N/A | N/A | | 54,280 | 66.2 | 65.4 - 66.9 |

| NAACCR CANADIAN COMBINED Subgroup | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|---|-------------------|-----|--------|-------|-----|--------|---------|------|-------------|
| | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 33,447 | 79.8 | 79.0 - 80.6 |
| Stage ² | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 8,618 | 94.1 | 92.7 - 95.3 |
| Regional | N/A | N/A | | N/A | N/A | | 2,470 | 65.3 | 62.7 - 67.7 |
| Distant | N/A | N/A | | N/A | N/A | | 865 | 15.8 | 13.1 - 18.6 |
| Unstaged | N/A | N/A | | N/A | N/A | | 16,224 | 78.1 | 76.9 - 79.2 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 1,661 | 90.5 | 88.6 - 92.1 |
| 45-54 | N/A | N/A | | N/A | N/A | | 5,119 | 88.8 | 87.6 - 89.9 |
| 55-64 | N/A | N/A | | N/A | N/A | | 11,447 | 87.7 | 86.8 - 88.5 |
| 65-74 | N/A | N/A | | N/A | N/A | | 9,662 | 80.6 | 79.4 - 81.8 |
| 75+ | N/A | N/A | | N/A | N/A | | 5,589 | 66.3 | 64.0 - 68.5 |

| NAACCR NORTH AMERICA COMBINED | MALES AND FEMALES | | | MALES | | | FEMALES | | |
|----------------------------------|-------------------|-----|--------|-------|-----|--------|---------|------|-------------|
| Subgroup | Count | RSR | 95% CI | Count | RSR | 95% CI | Count | RSR | 95% CI |
| Total | N/A | N/A | | N/A | N/A | | 384,798 | 78.1 | 77.8 - 78.3 |
| Stage ² | | | | | | | | | |
| Localized | N/A | N/A | | N/A | N/A | | 248,759 | 92.9 | 92.5 - 93.2 |
| Regional | N/A | N/A | | N/A | N/A | | 68,178 | 65.8 | 65.2 - 66.4 |
| Distant | N/A | N/A | | N/A | N/A | | 32,549 | 17.4 | 16.8 - 18.0 |
| Unstaged | N/A | N/A | | N/A | N/A | | 30,863 | 66.7 | 65.8 - 67.5 |
| Age Group ¹ | | | | | | | | | |
| 15-44 | N/A | N/A | | N/A | N/A | | 25,223 | 90.3 | 89.8 - 90.8 |
| 45-54 | N/A | N/A | | N/A | N/A | | 56,870 | 87.5 | 87.2 - 87.9 |
| 55-64 | N/A | N/A | | N/A | N/A | | 131,439 | 84.0 | 83.8 - 84.3 |
| 65-74 | N/A | N/A | | N/A | N/A | | 111,495 | 78.4 | 78.0 - 78.7 |
| 75+ | N/A | N/A | | N/A | N/A | | 59,869 | 66.2 | 65.4 - 66.9 |

Abbreviations: RSR, Relative Survival Ratio; CI, Confidence Interval

^{*} All statistics are suppressed when the standard error was greater than or equal to 10% or the difference between the upper and lower confidence intervals was greater than 40%.

Relative survival ratio (RSR) and confidence interval (CI) values are not age-standardized.

² Canadian data is comprised of 2015-2017 only due to changes in coding of stage starting in 2018.